Eton Pharmaceuticals, Inc.
ETON · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $22,459 | $18,928 | $17,282 | $11,647 |
| % Growth | 18.7% | 9.5% | 48.4% | – |
| Cost of Goods Sold | $14,604 | $7,004 | $7,421 | $5,171 |
| Gross Profit | $7,855 | $11,924 | $9,861 | $6,476 |
| % Margin | 35% | 63% | 57.1% | 55.6% |
| R&D Expenses | $1,112 | $3,712 | $1,161 | -$871 |
| G&A Expenses | $8,106 | $9,687 | $9,170 | $6,718 |
| SG&A Expenses | $8,106 | $9,687 | $9,170 | $6,718 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9,218 | $13,399 | $10,331 | $5,847 |
| Operating Income | -$1,363 | -$1,475 | -$470 | $629 |
| % Margin | -6.1% | -7.8% | -2.7% | 5.4% |
| Other Income/Exp. Net | -$592 | -$1,044 | -$1,028 | -$1,140 |
| Pre-Tax Income | -$1,955 | -$2,519 | -$1,498 | -$511 |
| Tax Expense | -$28 | $66 | $74 | $87 |
| Net Income | -$1,927 | -$2,585 | -$1,572 | -$598 |
| % Margin | -8.6% | -13.7% | -9.1% | -5.1% |
| EPS | -0.07 | -0.096 | -0.059 | -0.023 |
| % Growth | 27.2% | -64.3% | -155.5% | – |
| EPS Diluted | -0.07 | -0.096 | -0.059 | -0.023 |
| Weighted Avg Shares Out | 26,893 | 26,893 | 26,886 | 26,136 |
| Weighted Avg Shares Out Dil | 26,893 | 26,893 | 26,886 | 26,136 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,212 | $1,198 | $1,163 | $0 |
| Depreciation & Amortization | $1,009 | $1,005 | $1,013 | $355 |
| EBITDA | $266 | -$470 | $543 | $984 |
| % Margin | 1.2% | -2.5% | 3.1% | 8.4% |